Skip Navigation

Center for Chronic Lymphocytic Leukemia Clinical Research and Trials

  • Patients have the opportunity to participate in trials for new therapies for all phases of Chronic Lymphocytic Leukemia (CLL), including advanced CLL. These trials include:

    • Agents that prime CLL cells to die when they are hit with chemotherapy
    • Drugs that block key drivers of CLL cell growth, including kinase inhibitors

    Learn more about clinical trials for CLL patients.

    Translational science, which quickly moves laboratory findings into clinical practice, is also a key focus of the Center for Chronic Lymphocytic Leukemia. This includes:

    • Providing CLL samples to a large network of collaborators who are working to better understand how CLL develops and how we can best target it with the goal of finding a cure
    • Examining genetic material of a variety of CLLs in order to identify genetic changes that cause CLL

    Genetic Study of Familial Chronic Lymphocytic Lymphoma

    Dana-Farber is currently enrolling participants for a Genetic Study of Familial Chronic Lymphocytic Lymphoma. This study, led by Jennifer R. Brown, MD, PhD, seeks to identify the genes that cause the disease, in order to develop methods of prevention and diagnosis counseling. To be eligible, participants must have at least two first-degree relatives (e.g., parent, sibling, or child) who have a lymphoma or lymphoproliferative disorder. For more information, including detailed eligibility guidelines and participation requirements, contact lead investigator Jennifer R Brown, MD, PhD or study coordinator Alexander Vartanov.

    Learn more about the Harvard Study of Genetic Factors that Lead to Lymphoma

  • CLL Research News
    Catherine Wu, MD, comments on her latest research on CLL, including the impact of mutated SF3B1 on CLL-associated pathways.

  • Appointments and Second Opinions
    877-442-3324

    Make Appointment Online
    Dana-Farber/Brigham and Women's Cencer Center logo
    US News adult badge
  • Matthew Davids, MD, MMSc, on Advances in CLL Treatment
    Matthew Davids, MD, MMSc, of Dana-Farber’s Center for Chronic Lymphocytic Leukemia, shares updates on advances in treating newly-diagnosed and relapsed CLL. New approaches include ibrutinib + FCR for younger, newly-diagnosed patients and a combination of rituximab and venetoclax for relapsed patients.